MET and non-small cell lung carcinoma: Activating mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements of the anaplastic lymphoma kinase (ALK) gene are the most common drivers in nonsquamous NSCLC for which approved drugs are available, but mutations in BRAF and ERBB2, as well as MET gene amplification and MET exon skipping and ROS1 or RET gene fusions may also be potential targets for patient therapy [3,4].